Lurbinectedin-induced thrombocytopenia: the role of body surface area.
Cancer Chemother Pharmacol
; 89(5): 573-575, 2022 05.
Article
en En
| MEDLINE
| ID: mdl-35362793
ABSTRACT
Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m2 every 3 weeks. This recommendation was based on an exposure-response study, which demonstrated that patients with lower BSA had a higher incidence of thrombocytopenia. Herein we present the factors associated with BSA and thrombopoiesis, which may have contributed to the observed relationship.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trombocitopenia
/
Anemia
/
Neoplasias Pulmonares
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article